Skip Navigation


JAC Advance Access originally published online on April 8, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/5/708    most recent
dkh170v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fargion, S.
Right arrow Articles by Valenti, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fargion, S.
Right arrow Articles by Valenti, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 708-712
© 2004 The British Society for Antimicrobial Chemotherapy

Review

Treatment choices for people infected with HCV

Silvia Fargion*, Anna Ludovica Fracanzani and Luca Valenti

Dipartimento di Medicina Interna, Ospedale Maggiore IRCCS, Università di Milano, Via F Sforza 35, 20122 Milan, Italy

Hepatitis C virus (HCV) infection is one of the leading causes of liver disease in the world. It is a common cause of cirrhosis and hepatocellular carcinoma (HCC), as well as the most common reason for liver transplantation. Thus, appropriate therapeutic approaches have a strong clinical impact on the morbidity and mortality of HCV-infected patients. In this review we outline the most recent results in the therapy of HCV chronic hepatitis. Patients with the best prognostic factors treated with combination therapy (peginterferon and ribavirin) obtained a sustained response rate of 80–95%. We also provide some hints on the most promising results of the newest therapeutic options, which include molecules that inhibit specific enzymes, such as inhibitors of serine proteases, which are now in preclinical or early phase human trials. Host factors influencing the rate of response are also outlined.

Keywords: chronic hepatitis C, hepatitis C virus, interferon, ribavirin, anti-serine

* Corresponding author. Tel: +39-02-55033757; Fax: +39-02-50320296; E-mail: silvia.fargion{at}unimi.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
C.-M. Chen, Y. He, L. Lu, H. B. Lim, R. L. Tripathi, T. Middleton, L. E. Hernandez, D. W. A. Beno, M. A. Long, W. M. Kati, et al.
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4290 - 4296.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
G. Haqshenas, J. M. Mackenzie, X. Dong, and E. J. Gowans
Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome
J. Gen. Virol., January 1, 2007; 88(1): 134 - 142.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.